Strides Pharma gets USFDA EIR for its Bangalore flagship facility

Bangalore: Strides Pharma has announced that the Company's flagship facility (KRS Gardens) in Bangalore which was inspected by the USFDA in March 2020, has received the Establishment Inspection Report (EIR), thereby confirming the successful closure of the inspections. 

Strides, listed on the BSE Limited and National Stock Exchange of India Limited , is a global pharmaceutical company headquartered in Bangalore, India.

The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets.

The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. 

Read also: Strides Get USFDA Nod For Tetracycline Hydrochloride Capsules